Alumis Inc. (ALMS)

Real-time intraday values

Market Overview

From:

To:

ALMS Intraday

No data available

SymbolALMS

IPO DateJun 28, 2024

CEOMr. Martin Babler Ph.D.

Full Time Employees225

SectorHealthcare

IndustryBiotechnology

CountryUnited States

ExchangeNasdaqGS

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

Performance

Period	Return %	Value Change
1 Day	+15.74%	+3.29 US$
5 Days	+26.92%	+5.13 US$
1 Month	-2.70%	-0.67 US$
6 Months	+110.53%	+12.70 US$

Analyzing Market with AI

Evaluating the last 30 days of history and fundamental metrics of ALMS...

Key Statistics

Market Cap

3.08B

P/E Ratio

N/A

Div Yield

N/A

52W High

$30.60

52W Low

$2.76

Analyst Consensus

ConsensusBuy

Bullish1090.9%

Neutral19.1%

Bearish00.0%

52W Analyst Price Targets

Min Target
$25.00

Max Target
$55.00

Current$24.19

Avg Target$40.10

Analyst Recommendations

Target Price:$40.10($25.00 - $55.00)

Firm	Rating	Target Price	Upside Potential	Date
Chardan Capital	Buy	$40.00	+65.36%	5/19/2026
Wells Fargo	Overweight	$51.00	+110.83%	5/15/2026
Guggenheim	Buy	$34.00	+40.55%	5/15/2026
HC Wainwright & Co.	Neutral	$25.00	+3.35%	5/15/2026
Oppenheimer	Outperform	$55.00	+127.37%	3/30/2026
Chardan Capital	Buy	$38.00	+57.09%	3/30/2026
HC Wainwright & Co.	Buy	$25.00	+3.35%	3/30/2026
Morgan Stanley	Overweight	$38.00	+57.09%	3/20/2026
Chardan Capital	Buy	$38.00	+57.09%	3/20/2026
Raymond James	Strong Buy	$46.00	+90.16%	3/11/2026